Watch CYDY. Know when insiders buy.
One email the day a filing lands. Free.
CYDY
CytoDyn Inc.
0.19
−0.01 −5.00%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $262.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$42.7M −1240.2%NET DEBT $26.5M52W 0.19 – 0.37SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · May 31derived | — | — | — | −$5.6M | −$9.9M | — | 0.00 | −$4.9M | — | — | Aug 31 |
| Q3 2026 · Feb 28 | — | — | — | −$6.3M | −$4.7M | — | 0.00 | −$5.5M | — | — | Apr 8 |
| Q2 2026 · Nov 30 | — | — | — | −$21.7M | −$22.6M | — | -0.02 | −$4.3M | — | — | Apr 8 |
| Q1 2026 · Aug 31 | — | — | — | −$4.9M | −$5.5M | −128.8% | 0.00 | −$2.5M | — | — | Apr 8 |
| Q4 2025 · May 31derived | — | — | — | −$5.1M | −$6M | — | -0.01 | −$5.7M | — | — | Aug 31 |
| Q3 2025 · Feb 28 | — | — | — | −$4M | −$4.8M | — | 0.00 | −$5M | — | — | Apr 8 |
| Q2 2025 · Nov 30 | — | — | — | −$3.7M | −$4.8M | — | 0.00 | −$3.6M | — | — | Apr 8 |
| Q1 2025 · Aug 31 | — | — | — | $22.4M | $19.2M | — | 0.02 | $5.4M | — | — | Apr 8 |
| Q4 2024 · May 31derived | — | — | — | −$6.6M | −$16.8M | — | -0.01 | −$1.6M | — | — | Jul 25 |
| Q3 2024 · Feb 29 | — | — | — | −$3.4M | −$11.9M | — | -0.01 | −$2.3M | — | — | Apr 14 |
| Q2 2024 · Nov 30 | — | — | — | −$3.4M | −$9.6M | — | -0.01 | −$2.5M | — | — | Apr 14 |
| Q1 2024 · Aug 31 | — | — | — | −$4.6M | −$11.6M | — | -0.01 | −$4.5M | — | — | Apr 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to May 31 | — | — | −$38.6M | −$42.7M | — | -0.03 | −$17.3M | — | — | — | — |
| FY2025 · to May 31 | — | — | $9.7M | $3.7M | — | 0.00 | −$8.8M | — | — | — | — |
| FY2024 · to May 31 | — | — | −$18.1M | −$49.8M | — | -0.05 | −$11M | — | — | — | — |
| FY2023 · to May 31 | $0 | — | −$40.6M | −$79.8M | — | -0.10 | −$25.1M | — | — | — | — |
| FY2022 · to May 31 | $266K | 80.1% | −$145.4M | −$210.8M | -79255.6% | -0.31 | −$77.7M | — | — | — | — |
| FY2021 · to May 31 | $0 | — | −$104.6M | −$176.5M | — | -0.30 | −$117.6M | $122K | −$117.7M | — | — |
Every number comes from CytoDyn Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.